Cortexa, a joint venture of PharmAla Biotech and Vitura Health, is the first company specifically formed to address the needs of patients following the regulatory change put forward by the Australian TGA on February 3 allowing for specially authorized psychiatrists to prescribe MDMA and Psilocybin for PTSD and Treatment-resistant depression
Cortexa, a joint venture of PharmAla Biotech and Vitura Health, is the first company specifically formed to address the needs of patients following the regulatory change put forward by the Australian TGA on February 3 allowing for specially authorized psychiatrists to prescribe MDMA and Psilocybin for PTSD and Treatment-resistant depression